ProCE Banner Activity

CE

Understanding the Role of Mineralocorticoid Receptor Antagonists and the Impact on Patient Care in Chronic Kidney Disease in Type 2 Diabetes

Multimedia

In this interactive, on-demand webcast, experts provide insights on the evidence behind the use of finerenone in diabetic kidney disease, selecting appropriate patients for finerenone therapy, and strategies for overcoming clinical inertia.

Pharmacists : 1.50 contact {hours} ({0.15} CEUs)

Released: April 29, 2022

Expiration: April 28, 2023

No longer available for credit.

Share

Faculty

Diana Isaacs

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Joshua J. Neumiller

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Provided by

Provided by ProCE, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Target Audience

The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with CKD and T2D as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the pathophysiology and renal and cardiovascular outcomes of mineralocorticoid receptor activation in chronic kidney disease in patients with type 2 diabetes
  • Evaluate the safety and efficacy evidence of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone
  • Compare the clinical differences between steroidal and selective nonsteroidal mineralocorticoid receptor antagonists
  • Identify appropriate candidates for finerenone and strategies to implement use, including multidisciplinary care and overcoming clinical inertia

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, has disclosed that she has received consulting fees from Abbott, Dexcom, Insulet, Klinio, Medtronic, and Novo Nordisk.

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, has disclosed that he has received consulting fees from Bayer, Dexcom, Novo Nordisk, and Sanofi.

Staff Disclosure

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP has no relevant conflicts of interest to report.

Ruth Cohen,

Ruth Cohen Cooper, CHCP has no relevant conflicts of interest to report.

Instructions for Credit

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-093-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure of Unlabeled Use

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 29, 2022, through April 28, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 29, 2022, through April 28, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge and competence of pharmacists about pathophysiology of mineralocorticoid receptor activation in CKD in patients with T2D and the impact of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone on patient care.